Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
NCT01922089
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
498
Enrollment
INDUSTRY
Sponsor class
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
DRUG:
LCZ696
Sponsor
Novartis Pharmaceuticals